Part 2: The Spaces Between

Key Takeaways

• Only 15% of eligible patients receive SGLT2 inhibitors.
• Over $3 billion invested in early‑stage CKM infrastructure startups.
• Datavant links labs, pharmacy, claims, and EHR data at scale.
• Kidney‑related M&A exceeded $20 billion in the past two years.
• Bright Frontier funds companies building bridges across CKM care continuum.

Pulse Analysis

Chronic kidney disease (CKD) affects roughly 15% of U.S. adults and drives a disproportionate share of cardiovascular mortality and health‑care spending. Early biomarkers—rising creatinine, proteinuria, electrolyte shifts—are detectable long before patients require dialysis or hospitalization, yet primary‑care screening rates remain below 50%. This disconnect creates a costly lag where preventable complications emerge, inflating Medicare expenditures by an estimated $120 billion annually. Recognizing CKD as the body’s early warning system reframes it from a downstream problem to a strategic point for risk mitigation.

The Bright Frontier analysis identifies four "bridges" where the CKM care continuum breaks down. The first bridge—turning raw signals into actionable decisions—requires interoperable data platforms; companies like Datavant are stitching together lab, pharmacy, claims, and electronic health‑record streams to surface actionable risk scores. The second bridge focuses on translating decisions into treatment, yet only 15% of eligible patients receive SGLT2 inhibitors, highlighting fragmentation across specialties. The third bridge demands accountability, linking outcomes to reimbursement, a gap that firms such as Turquoise Health and Arbital Health are addressing with transparent pricing and outcomes‑based contracts. Finally, the feedback loop—accountability to signal—needs real‑world evidence engines like Truveta to inform future guidelines and close the learning cycle.

Investment momentum underscores the market’s shift. In the last two years, more than $20 billion has flowed through kidney‑focused mergers and acquisitions, while early‑stage CKM infrastructure startups have attracted over $3 billion. Bright Frontier’s platform aims to channel capital toward companies that build the connective tissue across these bridges, accelerating value‑based care models and fostering a learning health system. As payment reforms reward outcomes rather than volume, firms that can demonstrate measurable impact will capture the next wave of growth, reshaping how kidney and cardiometabolic diseases are prevented, treated, and managed.